ArticleBMC infectious diseases2026
Trends in vancomycin-resistant Enterococcus faecium and methicillin-resistant Staphylococcus aureus and their association with vancomycin / linezolid consumption in a tertiary hospital in China.
Article in BMC infectious diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Article
- A retrospective analysis of pathogen distribution and antimicrobial resistance trends of bacteria in a tertiary hospital in China, 2021-2025.Frontiers in cellular and infection microbiology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAntimicrobial resistance is a major global public health challenge. Vancomycin-resistant Enterococcus faecium (VR-Efm) is a significant cause of healthcare-associated infections. To investigate the incidence density of VR-Efm and methicillin-resistant Staphylococcus aureus (MRSA), and to analyze their correlation with vancomycin and linezolid antimicrobial consumption (defined daily doses per 1,000 patient-days), thereby providing evidence for developing effective infection prevention and antimicrobial stewardship strategies.
methodsA retrospective analysis was conducted to investigate the epidemiology of VR-Efm and MRSA from 2019 to the first and second quarters of 2025 (2025 Q1-Q2) in a tertiary care hospital in China. Correlation analyses were performed to assess the relationships between VR-Efm and MRSA incidence density and the consumption of vancomycin and linezolid, respectively.
resultsThe vancomycin resistance rate among Enterococcus faecium isolates showed an upward trend, increasing from 1.6% in 2019 to 23.1% in 2025 Q1-Q2. Linezolid resistance was first identified during 2025 Q1–Q2, with a resistance rate of 1.9%. A significant positive correlation was observed between linezolid consumption and the incidence density of VR-Efm (ρ = 0.779, n = 7, p = 0.039). However, no significant association was found between vancomycin consumption and VR-Efm incidence density (ρ = -0.022, n = 7, p = 0.963). No significant correlation was found between MRSA incidence density and the consumption of vancomycin (ρ = -0.490, n = 7, p = 0.265) or linezolid (ρ = -0.190, n = 7, p = 0.683).
conclusionsThe increasing vancomycin resistance rate of Enterococcus faecium, along with the emergence of linezolid-resistant strains, warrants heightened attention and strategic action. Strengthened hospital infection control measures targeting VR-Efm are urgently needed, along with the rational use of linezolid as a key strategy to mitigate antimicrobial selection pressure.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.